Presentation of the year-end report for the fiscal year 2015:

Date: Monday February 8, 2016 / kl. 16:00

Venue: Online Presentation

Topic: C-RAD year-end Report 2015

Procedure:

Please register until February 8, 2016 / kl. 14:00 via email to investors@c-rad.com

After your registration you will receive a confirmation via email.

The login data will be distributed to all participants 15 min prior to the meeting.

A recording of the presentation will be made accessible on the C-RAD website after the presentation.

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 40. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visitwww.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

C-RAD AB issued this content on 27 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 27 January 2016 08:24:28 UTC

Original Document: https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=693795&lang=en